It passes all visual inspection standards for quality
Why the Combination Is Common Anyway The pairing is popular in research and clinic marketing because CJC-1295 and Ipamorelin target different growth-hormone signaling pathways: Compound Class Primary Pathway FDA Status CJC-1295 GHRH analog GHRH receptor signaling Not approved Ipamorelin GHRP / ghrelin mimetic GHS-R1a signaling Not approved CJC-1295 + Ipamorelin Combination research blend Dual pathway GH secretagogue model Not approved Mechanistic complementarity is not the same as regulatory approval
Downstream IGF-1 Pathway Activation Growth hormone released from the pituitary acts on peripheral tissues, especially the liver, to stimulate production of insulin-like growth factor 1
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
doi: 10.3390/ijms25115747 112 ChenSSaeedAFUHLiuQJiangQXuHXiaoGGet al
